Reference
- Panda FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J. Med. 338,853–860 (1998).
- Masur H, Kaplan JE, Holmes KK. US Public Health Service; Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons — 2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann. Intern. Med. 3;137(5 Part 2), 435–478 (2002).
- Lange CG, Lederman MM. Immune reconstitution with antiretroviral therapies in chronic HIV-infection. J. Antimicrob. Chemother. 51,1–4 (2003).
- Lange CG, Valdez H, Medvik K, et al. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin. Immunol. 102,154–161 (2002).
- Pett SL, Kelleher A. Cytokine therapies in HIV-1 infection, present and future. Expert Rev. Anti-infect. Ther. 1(1), 89–102 (2003).
- French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 6,1293–1297 (1992).
- French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 1, 107–115 (2000).
- Gasim S, Elhassan AM, Kharazmi A, et al. The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin. Exp. Immunol. 119,523–529 (2000).
- Desimone JA, Babinchak TJ, Kaulback KR, et al. Treatment of mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. AIDS Patient Care STDs 17(12), 617–622 (2003).
- French MA, Lewin SR, Dykstra C, et al. Grave's disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Res. Hum. Retroviruses 20(2), 157–162 (2004).
- Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin. Infect. Dis. 34,224–233 (2002).
- Stone SF, Price P, Keane NM, et al. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med. 3,21–27 (2002).
- Stone SF, Price P Cytomegalovirus retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J. Infect. Dis. 185,1813–1817 (2001).
- Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 16,2043–2047 (2002).
- Bellamy R. Susceptibility to mycobacterial infections: the importance of host genetics. Genes Immun. 4,4–11 (2003).
- Cinque P, Bossoclasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J. NeuroviroL 9\(Suppl. 1), 73–80 (2003).
Website
- The Adult AIDS Clinical Trials Group http://aactg.s-3.com Accessed May 2004